Nasopharyngeal lymphoma is a lymphoproliferative neoplasm involving the Waldeyer ring (nasopharynx, tonsils, tongue base). The Waldeyer ring is the most common localization of extranodal lymphomas. NHL subtypes (especially DLBCL and NK/T-cell lymphoma) are much more common than Hodgkin lymphoma. NK/T-cell lymphoma is EBV-associated and endemic in Asian populations. On CT/MRI, it appears as a homogeneous soft tissue mass in the nasopharynx. The most important differentiation from NPC is minimal or absent bone erosion — lymphoma wraps around bone while carcinoma erodes it. DWI shows marked diffusion restriction (high cellularity). FDG-PET is critically important for staging and treatment response.
Age Range
40-75
Peak Age
60
Gender
Male predominant
Prevalence
Rare
Nasopharyngeal lymphoma develops from clonal proliferation of lymphocytes in the mucosa-associated lymphoid tissue (MALT) or regional lymph nodes of the Waldeyer ring. In DLBCL, mature B lymphocytes proliferate uncontrollably forming a dense cellular mass — this high cellularity is the cause of marked diffusion restriction on DWI. In NK/T-cell lymphoma, EBV-infected NK or T cells show angiodestructive growth pattern — developing vessel wall invasion and necrosis. Lymphoma's wrapping around bone without eroding it results from lymphoid cells not triggering osteoclast activation needed for bone resorption — this is the fundamental difference from carcinomas. Homogeneous enhancement reflects the tumor's uniform vascular structure; necrosis is rare in DLBCL (more common in NK/T-cell lymphoma). FDG uptake results from high metabolic activity (glucose metabolism) of lymphocytes — DLBCL is one of the lymphoma subtypes showing highest FDG avidity.
The triple combination of homogeneous soft tissue mass in nasopharynx + absent bone erosion + marked DWI restriction (ADC <0.7) is the signature finding of nasopharyngeal lymphoma. Most reliable finding set distinguishing from NPC.
Marked diffusion restriction on DWI — the most reliable and earliest MR finding of lymphoma. ADC value is typically <0.7 × 10⁻³ mm²/s (DLBCL) or <0.6 × 10⁻³ mm²/s (NK/T-cell). Can be differentiated from NPC by lower ADC values. In treatment response, ADC increase indicates complete response, persistent low ADC indicates residual disease.
Report Sentence
The nasopharyngeal mass demonstrates marked diffusion restriction on DWI (ADC: ___ × 10⁻³ mm²/s), consistent with lymphoproliferative disease.
Homogeneously enhancing nasopharyngeal mass on CT — minimal or no bone erosion. This is the most important distinguishing feature from NPC. Lymphoma wraps around bone rather than infiltrating it. Necrosis is rare in DLBCL (more common in NK/T-cell lymphoma). Bilateral cervical LAP frequently accompanies.
Report Sentence
A homogeneously enhancing soft tissue mass is identified in the nasopharynx without significant bone erosion; lymphoproliferative disease is the leading consideration.
Intense FDG uptake on PET-CT (SUVmax typically >10-15). DLBCL is among lymphoma subtypes showing highest FDG avidity. Whole-body PET-CT is critical for staging (Ann Arbor), treatment response assessment (Deauville criteria), and recurrence detection. Waldeyer ring + cervical + distant nodal + extranodal involvement evaluated in single session.
Report Sentence
The nasopharyngeal mass demonstrates intense metabolic activity on FDG-PET (SUVmax: ___); whole-body evaluation has been performed for Ann Arbor staging.
Homogeneous post-gadolinium enhancement — reflects DLBCL's uniform cell distribution and regular vascular architecture. Necrosis is rare (different from carcinoma). In NK/T-cell lymphoma, necrosis and heterogeneous enhancement may be seen due to angiodestructive pattern.
Report Sentence
The nasopharyngeal mass demonstrates homogeneous post-gadolinium enhancement without necrosis; may be consistent with DLBCL.
Isointense or mildly hyperintense signal to muscle on T2. Isointense or mildly hypointense on T1. Lymphoma's homogeneous cellular structure leads to uniform MR signal pattern. In necrotic NK/T-cell lymphoma, T2 signal may be more heterogeneous.
Report Sentence
The mass shows isointense signal to muscle on T1 and mildly hyperintense homogeneous signal on T2, consistent with lymphoproliferative disease.
Criteria
Most common NHL subtype. Large B lymphocytes, high Ki-67. Most common lymphoma in Waldeyer ring.
Distinct Features
Homogeneous enhancement, necrosis rare, very low ADC. High response rate with R-CHOP. 5-year survival 60-70%.
Criteria
EBV associated. Angiodestructive growth. Endemic in Asian populations. Nasal cavity + nasopharynx involvement.
Distinct Features
Necrosis common (angiodestruction), heterogeneous enhancement, midline destruction (lethal midline granuloma). SMILE protocol + RT.
Criteria
Waldeyer ring involvement rare (1-4%). Reed-Sternberg cells. Young adult.
Distinct Features
Mediastinal LAP frequently accompanies. FDG avid. ABVD chemotherapy. Excellent prognosis (85-90% survival).
Distinguishing Feature
NPC shows prominent bone erosion, perineural spread; lymphoma has minimal/no bone erosion
Distinguishing Feature
Adenoid hypertrophy symmetric, no DWI restriction, pediatric; lymphoma may be asymmetric, marked DWI restriction
Distinguishing Feature
Metastasis has known primary, heterogeneous enhancement; lymphoma has homogeneous mass, B symptoms, Waldeyer ring involvement
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
specialist-referralNasopharyngeal lymphoma shows high sensitivity to chemotherapy. R-CHOP for DLBCL, SMILE protocol + consolidative RT for NK/T-cell lymphoma are standard treatments. Ann Arbor staging and IPI (International Prognostic Index) are prognostic tools. PET-CT is used with Deauville criteria for treatment response assessment. Histopathological subtype determination by excisional/incisional biopsy is mandatory for treatment planning.
Nasopharyngeal lymphoma shows high sensitivity to chemotherapy. R-CHOP for DLBCL, SMILE protocol + radiotherapy for NK/T-cell lymphoma are standard treatments. Ann Arbor staging is used. PET-CT is critical for treatment response assessment (Deauville criteria). Five-year survival is 60-70% for DLBCL and 50-60% for NK/T-cell lymphoma.